Titlebook: Risk-Benefit Analysis in Drug Research; Proceedings of an In J. F. Cavalla (Research Director) Conference proceedings 1981 MTP Press Limite

ciliary-body

The prospect of product liability,s. The first is that one can only speculate at this stage on what the ultimate law will be as only a draft of the EEC directive is available and even when it is finalized there will be a degree of flexibility in how it is implemented in UK legislation. The second concern is that, in expressing any b

MORPH

樂意

Preclinical requirements,edicine which should be available before it can be tested in human subjects and then before it can be marketed. The universality of this debate is exemplified by the fact that in Scrip of 9 February Mr Patrick Jenkin, the UK Secretary of State for Social Services, was quoted as expressing‘his concer

Traumatic-Grief

敘述

auxiliary

Outspoken

Preclinical requirements,s to quote from it out of context but one particularly telling sentence read, ‘There may be a case for cutting back on animal testing but if so, it is only on quantity in a limited number of respects and not at all on quality’.

faddish

The effect on the public,equences of the operations of other industries — pollution of water from paper mills, motor car exhausts, chemicals in the environment and so on. I think the industry will be better able to face the difficult years ahead if it can somehow recognize that it hasn’t been singled out, by public opinion, for a unique place in some public pillory.

賭博

,New-drug assessment in man: a clinical pharmacologist’s view,ts prosperity. Currently both parties, clinical pharmacology and industry feel threatened by a third party, governmental drug regulatory authorities. The purpose of this article is to delineate problems currently faced by the clinical pharmacologist in new drug assessment and to suggest some possible solutions.

ornithology

Problems facing a regulatory authority,atment of acute gout. Immediately, therefore, one sees that there are many factors to weigh up and decisions become very difficult. The controversy which ensues can be seen from the strong reaction that industry makes to the efforts of regulatory authorities. as epitomized by the following two views: